Valuation: Avicanna Inc.

Market Cap 16.13M 11.35M 9.93M 9.12M 8.5M 1.08B 16.37M 110M 42.57M 531M 42.62M 41.7M 1.83B P/E 2024
-8.43x
P/E 2025 -9.36x
Enterprise Value 15.85M 11.16M 9.75M 8.96M 8.35M 1.06B 16.09M 108M 41.83M 522M 41.87M 40.98M 1.8B EV / Sales 2024
1.31x
EV / Sales 2025 1.03x
Free-Float
77.41%
Yield 2024 *
-
Yield 2025 -
1 day-7.69%
Current month-4.00%
1 month-4.00%
3 months-20.00%
6 months-45.45%
Current year-46.67%
1 week 0.12
Extreme 0.115
0.13
1 month 0.1
Extreme 0.105
0.14
Current year 0.1
Extreme 0.105
0.24
1 year 0.1
Extreme 0.105
0.31
3 years 0.1
Extreme 0.105
0.6
5 years 0.1
Extreme 0.105
1.01
10 years 0.1
Extreme 0.105
7.4
Manager TitleAgeSince
Sales & Marketing - 2015-04-30
Chief Executive Officer 39 2016-11-25
Director of Finance/CFO - 2025-09-14
Director TitleAgeSince
Chairman 39 2016-11-25
Director/Board Member - 2018-10-21
Director/Board Member - 2025-12-31
Date Insider Type Main position Quantity % Market Cap.
06-17Buy

Chief Financial Officer

-65,079 0.0517%
06-17Option

Founder

75,000 0.0596%
06-17Buy

Director

225,500 0.1793%
Change 5-day change 1-year change 3-year change Capi.($)
-7.69%0.00%-55.56%-61.29% 12.32M
+1.70%+7.41%+3.12%+8.46% 49.15B
+0.92%+3.93%+399.71%+605.33% 40.23B
+1.89%+8.32%+26.06%-6.35% 34.55B
+2.38%+6.35%+21.25%+64.58% 33.09B
+3.96%+10.67%+11.89%+38.86% 25.19B
+2.51%+5.27% - - 17.05B
+2.58%+5.79%+73.44%+133.27% 15.92B
+0.32%+0.58%+13.67%+19.09% 13.83B
+3.30%+0.76%+90.23%+99.12% 13.52B
Average +1.19%+5.41%+64.87%+100.12% 24.25B
Weighted average by Cap. +2.05%+6.10%+91.87%+139.21%

Financials

2024 2025
Net sales 25.46M 17.92M 15.67M 14.4M 13.42M 1.71B 25.85M 173M 67.21M 839M 67.28M 65.84M 2.89B 25.48M 17.94M 15.68M 14.41M 13.43M 1.71B 25.87M 173M 67.26M 840M 67.33M 65.89M 2.89B
Net income -3.62M -2.55M -2.23M -2.05M -1.91M -243M -3.67M -24.57M -9.55M -119M -9.56M -9.36M -411M -2.76M -1.94M -1.7M -1.56M -1.45M -185M -2.8M -18.74M -7.28M -90.92M -7.29M -7.14M -313M
Net Debt -339K -239K -209K -192K -179K -22.71M -344K -2.3M -894K -11.16M -895K -876K -38.47M -281K -198K -173K -159K -148K -18.81M -285K -1.91M -741K -9.25M -742K -726K -31.86M
Logo Avicanna Inc.
Avicanna Inc. is a commercial-stage international biopharmaceutical company. It focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. It has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.
Employees
112
Date Price Change Volume
26-07-03 $0.1200 -7.69% 81,275
26-07-02 $0.1300 +4.00% 239,701
26-06-30 $0.1250 0.00% 349,800
26-06-29 $0.1250 +4.17% 205,000
26-06-26 $0.1200 -4.00% 489,545
  1. Stock Market
  2. Stocks
  3. AVCN Stock